Belinostat – Uses, Dosage, Side Effects, Interactions

Last updated: February 8, 2026Reviewed date: February 8, 2026Reading time: 58 min read
Patient Tools

Read, save, and share this guide

Use these quick tools to make this medical article easier to read, print, save, or share with a family member.

Belinostat - Uses, Dosage, Side Effects, Interactions
Patient Mode

Understand this article easily

Switch between simple English and easy Bangla patient notes. This is for education and does not replace a doctor consultation.

Belinostat is an intravenously administered histone deacetylase inhibitor and antineoplastic agent that is approved for use in refractory or relapsed peripheral T-cell lymphoma. Belinostat is associated with a moderate rate of minor serum enzyme elevations during therapy and has been reported to cause clinically apparent...

For severe symptoms, danger signs, pregnancy, child illness, or sudden worsening, seek urgent medical care.

বাংলা রোগী নোট এখনো যোগ করা হয়নি। পোস্ট এডিটরে “RX Bangla Patient Mode” বক্স থেকে সহজ বাংলা সারাংশ যোগ করুন।

এই তথ্য শিক্ষা ও সচেতনতার জন্য। এটি ডাক্তারি পরীক্ষা, রোগ নির্ণয় বা প্রেসক্রিপশনের বিকল্প নয়।

Article Summary

Belinostat is an intravenously administered histone deacetylase inhibitor and antineoplastic agent that is approved for use in refractory or relapsed peripheral T-cell lymphoma. Belinostat is associated with a moderate rate of minor serum enzyme elevations during therapy and has been reported to cause clinically apparent fatal, acute liver injury. Belinostat is a novel hydroxamic acid-type histone deacetylase (HDAC) inhibitor with antineoplastic activity. Belinostat targets HDAC...

Key Takeaways

  • This article explains Mechanism of Action in simple medical language.
  • This article explains Indications in simple medical language.
  • This article explains Contraindications in simple medical language.
  • This article explains Dosage in simple medical language.
Educational health guideWritten for patient understanding and clinical awareness.
Reviewed content workflowUse writer and reviewer profiles for stronger trust.
Emergency safety firstUrgent warning signs are highlighted below.

Seek urgent medical care if you notice

These warning signs are general safety guidance. Local emergency numbers and clinical judgment should always come first.

  • Severe symptoms, breathing difficulty, fainting, confusion, or rapidly worsening illness.
  • New weakness, severe pain, high fever, or symptoms after a serious injury.
  • Any symptom that feels urgent, unusual, or unsafe for the patient.
1

Emergency now

Use emergency care for severe, sudden, rapidly worsening, or life-threatening symptoms.

2

See a doctor

Book a professional medical evaluation if symptoms persist, worsen, recur often, affect daily activities, or occur in a high-risk patient.

3

Learn safely

Use this article to understand possible causes, tests, treatment options, prevention, and questions to ask your clinician.

Before reading

RX Patient Tools

Use these quick guides before reading the article, or return to them when you need help preparing questions for a doctor.

Start here Choose the right pathway for symptoms, reports, medicines, or urgent warning signs. Disease article roadmap Read this topic step by step: meaning, symptoms, warning signs, diagnosis, treatment, prevention, and follow-up. Treatment planner Prepare questions about treatment choices, benefits, risks, side effects, and follow-up. Family & caregiver guide Organize symptoms, reports, medicines, questions, and follow-up safely. Nutrition & diet guide Prepare food, hydration, supplement, and medicine-timing questions safely. Prevention guide Organize risk factors, protective habits, screening, and warning signs. Recovery guide Prepare a safe plan for activity, rehabilitation, warning signs, and follow-up.
Definition

Belinostat is an intravenously administered histone deacetylase inhibitor and antineoplastic agent that is approved for use in refractory or relapsed peripheral T-cell lymphoma. Belinostat is associated with a moderate rate of minor serum enzyme elevations during therapy and has been reported to cause clinically apparent fatal, acute liver injury.

Belinostat is a novel hydroxamic acid-type histone deacetylase (HDAC) inhibitor with antineoplastic activity. Belinostat targets HDAC enzymes, thereby inhibiting tumor cell proliferation, inducing apoptosis, promoting cellular differentiation, and inhibiting angiogenesis. This agent may sensitize drug-resistant tumor cells to other antineoplastic agents, possibly through a mechanism involving the down-regulation of thymidylate synthase.

Belinostat is a hydroxamic acid-type histone deacetylase (HDAC) inhibitor with antineoplastic activity. It has a role as an antineoplastic agent and an EC 3.5.1.98 (histone deacetylase) inhibitor. It is a hydroxamic acid, a sulfonamide, and an olefinic compound.

Belinostat is a novel agent that inhibits the enzyme histone deacetylase (HDAC) with a sulfonamide-hydroxide structure. It was developed as an orphan drug to target hematological malignancies and solid tumors by TopoTarget. The safety and efficacy of belinostat are currently being evaluated for use in combination with traditional front-line therapies for the treatment of PTCL. Intravenous administration of the agent is available as Beleodaq as monotherapy and the dosing regimen involves a 21-day cycle. It was US-approved in July 2014 as a therapeutic agent for relapsed or refractory peripheral T-cell lymphoma.

Mechanism of Action

Belinostat inhibits the activity of histone deacetylase (HDAC) thus preventing the removal of acetyl groups from the lysine residues of histones and some non-histone proteins. In vitro, belinostat caused the accumulation of acetylated histones and other proteins and increased the expression of tumor-suppressor genes. It ultimately induces cell cycle arrest, inhibition of angiogenesis, and/or apoptosis of some transformed cells.

Beleodaq is a histone deacetylase (HDAC) inhibitor that exhibits pan-HDAC inhibition and potent growth inhibitory and pro-apoptotic activities in a variety of tumor cells, including PTCL cells, at nanomolar concentrations. None of the trials show any clinically relevant changes caused by Beleodaq on heart rate, PR duration, or QRS duration as measures of autonomic state, atrioventricular conduction or depolarization; there were no cases of Torsades de Pointes.

Indications

  • Belinostat is indicated for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL) with a manageable safety profile. It is a potential alternative therapy for patients who did not experience adequate response to first-line drugs for PTCL. It can be used in patients with baseline platelet count, which can increase bleeding risk. সহজ বাংলা: প্লাটিলেট কম।" data-rx-term="thrombocytopenia" data-rx-definition="Thrombocytopenia means low platelet count, which can increase bleeding risk. সহজ বাংলা: প্লাটিলেট কম।">thrombocytopenia.
  • Belinostat is an intravenously administered histone deacetylase inhibitor and antineoplastic agent that is approved for use in refractory or relapsed peripheral T-cell lymphoma. Belinostat is associated with a moderate rate of minor serum enzyme elevations during therapy and has been reported to cause clinically apparent fatal, acute liver injury.
  • Relapsed or refractory peripheral T-cell lymphoma

Use in Cancer

Belinostat is approved to treat:

  • Peripheral T-cell lymphoma in patients whose disease has recurred (come back) or is refractory (does not respond to treatment).

This use is approved under FDA’s Accelerated Approval Program. As a condition of approval, a confirmatory trial(s) must show that belinostat provides a clinical benefit in these patients.

Belinostat is also being studied in the treatment of other types of cancer.

Contraindications

  • Anemia, bone marrow suppression, leukopenia, bacterial infection. সহজ বাংলা: ব্যাকটেরিয়ার বিরুদ্ধে লড়াই করা শ্বেত রক্তকণিকা।" data-rx-term="neutrophil" data-rx-definition="Neutrophil is a white blood cell important for fighting bacterial infection. সহজ বাংলা: ব্যাকটেরিয়ার বিরুদ্ধে লড়াই করা শ্বেত রক্তকণিকা।">neutrophil count, which may increase infection risk. সহজ বাংলা: নিউট্রোফিল কম থাকা, সংক্রমণের ঝুঁকি বাড়তে পারে।" data-rx-term="neutropenia" data-rx-definition="Neutropenia means low neutrophil count, which may increase infection risk. সহজ বাংলা: নিউট্রোফিল কম থাকা, সংক্রমণের ঝুঁকি বাড়তে পারে।">neutropenia, platelet count, which can increase bleeding risk. সহজ বাংলা: প্লাটিলেট কম।" data-rx-term="thrombocytopenia" data-rx-definition="Thrombocytopenia means low platelet count, which can increase bleeding risk. সহজ বাংলা: প্লাটিলেট কম।">thrombocytopenia – Hematologic toxicity, including platelet count, which can increase bleeding risk. সহজ বাংলা: প্লাটিলেট কম।" data-rx-term="thrombocytopenia" data-rx-definition="Thrombocytopenia means low platelet count, which can increase bleeding risk. সহজ বাংলা: প্লাটিলেট কম।">thrombocytopenia, leukopenia (bacterial infection. সহজ বাংলা: ব্যাকটেরিয়ার বিরুদ্ধে লড়াই করা শ্বেত রক্তকণিকা।" data-rx-term="neutrophil" data-rx-definition="Neutrophil is a white blood cell important for fighting bacterial infection. সহজ বাংলা: ব্যাকটেরিয়ার বিরুদ্ধে লড়াই করা শ্বেত রক্তকণিকা।">neutrophil count, which may increase infection risk. সহজ বাংলা: নিউট্রোফিল কম থাকা, সংক্রমণের ঝুঁকি বাড়তে পারে।" data-rx-term="neutropenia" data-rx-definition="Neutropenia means low neutrophil count, which may increase infection risk. সহজ বাংলা: নিউট্রোফিল কম থাকা, সংক্রমণের ঝুঁকি বাড়তে পারে।">neutropenia and lymphopenia), and anemia have been reported with belinostat therapy. Monitor complete blood cell counts prior to starting therapy and then weekly. Dose modifications may be necessary in patients with bone marrow suppression and should be determined by the absolute neutrophil count (ANC) and platelet count nadirs of the previous cycle of therapy. Platelet counts should be >= 50,000/mm3 and ANC > 1000/mm3 before starting each cycle.
  • Chemotherapy, infection, sepsis – Serious infections, including pneumonia and sepsis, have occurred during treatment with belinostat; some occurrences have been fatal. Do not administer belinostat to patients with an active infection. Use caution in patients with a history of extensive or intensive chemotherapy, as they may be at higher risk of life-threatening infections.
  • Hepatic disease – Abnormal liver function tests and fatal hepatic toxicity have been observed in patients receiving belinostat. Monitor liver function tests prior to the start of each cycle of therapy. Patients with signs of hepatic impairment or hepatic disease may require dose modification or discontinuation.
    Tumor lysis syndrome (TLS) – Tumor lysis syndrome (TLS) has occurred in patients treated with belinostat. Patients with high tumor burden or advanced-stage disease are at greater risk for developing TLS; consider tumor lysis prophylaxis with anti-hyperuricemic agents and hydration beginning 12—24 hours prior to treatment with belinostat in these patients. For TLS treatment, administer aggressive intravenous hydration and antihyperuricemic agents, correct electrolyte abnormalities, and monitor renal function.

Dosage

Strengths: 500 mg

Lymphoma

  • 1,000 mg/m2 IV over 30 minutes once daily on days 1 to 5 of a 21-day cycle
  • Duration of therapy: Repeat the cycle every 21 days until disease progression or unacceptable toxicity.
  • Dose reduction, discontinuation, or interruption of therapy may be needed to manage adverse reactions.

Dose Adjustments

Hematologic toxicities:

  • Nadir absolute bacterial infection. সহজ বাংলা: ব্যাকটেরিয়ার বিরুদ্ধে লড়াই করা শ্বেত রক্তকণিকা।" data-rx-term="neutrophil" data-rx-definition="Neutrophil is a white blood cell important for fighting bacterial infection. সহজ বাংলা: ব্যাকটেরিয়ার বিরুদ্ধে লড়াই করা শ্বেত রক্তকণিকা।">neutrophil count less than 0.5 x 10(9)/L or platelet count less than 25 x 10(9)/L: Decrease dose by 25% (750 mg/m2)

Non-hematologic toxicities:

  • Any Grade 3 or 4 adverse reaction: Decrease dose by 25% (750 mg/m2)
  • Recurrence of Grade 3 or 4 adverse reaction after 2 dose reductions: Discontinue treatment

Patients with Reduced UGT1A1 Activity:

  • Reduce the starting dose to 750 mg/m2 in patients known to be homozygous for the UGT1A1*28 allele.

Side Effects

The Most Common

  • nausea
  • diarrhea
  • vomiting
  • constipation
  • pain in the head or upper neck. সহজ বাংলা: মাথাব্যথা।" data-rx-term="headache" data-rx-definition="Headache means pain in the head or upper neck. সহজ বাংলা: মাথাব্যথা।">headache
  • tiredness
  • decreased appetite
  • pain at the injection site
  • swelling of the hands, feet, or ankles
  • rash
  • fever, cough, chills, muscle aches, worsening skin problems, flu-like symptoms, or other signs of infection
  • painful, frequent, burning or difficult urination
  • unusual bleeding or bruising
  • dizziness, weakness, excessive tiredness, pale skin, or shortness of breath
  • yellowing of the skin or eyes, pain in the right upper stomach area, dark urine, or itching

More Common

  • severe ongoing nausea, vomiting, or diarrhea;
  • a fever, chills, muscle aches, flu-like symptoms,
  • cough with mucus, chest pain, fast heartbeats, rapid breathing or shortness of breath;
  • easy bruising, unusual bleeding, purple or red spots under your skin;
  • pain or burning when you urinate;
  • confusion, severe drowsiness, feeling very ill;
  • liver problems–loss of appetite, stomach pain (upper right side), tiredness, itching, dark urine, clay-colored stools, jaundice (yellowing of the skin or eyes);
  • low red blood cells (anemia)–pale skin, unusual tiredness, feeling light-headed or short of breath, cold hands and feet; or
  • signs of tumor cell breakdown–tiredness, weakness, muscle cramps, nausea, vomiting, diarrhea, fast or slow heart rate, tingling in your hands and feet or around your mouth.

Rare

  • chest pain
  • confusion
  • cough
  • decreased urine
  • dizziness, faintness, or lightheadedness when getting up suddenly from a lying or sitting position
  • dry mouth
  • fainting
  • fast heartbeat
  • fever or chills
  • increased thirst
  • irregular heartbeat
  • loss of appetite
  • mood changes
  • muscle pain or cramps
  • nausea or vomiting
  • numbness or tingling in the hands, feet, or lips
  • pale skin
  • pinpoint red spots on the skin
  • rapid, shallow breathing
  • sore throat
  • sweating
  • tenderness
  • tightness in the chest
  • troubled breathing with exertion
  • unusual bleeding or bruising
  • unusual tiredness or weakness
  • unusual weight gain or loss

Drug Interaction

Pregnancy and Lactation

Pregnancy

Belinostat can cause fetal harm including teratogenicity and/or embryo-fetal death if administered during pregnancy, based on its mechanism of action. Reproductive animal studies have not been conducted with belinostat and there is no data in pregnant humans; however, it is a genotoxic drug that actively targets dividing cells. Women of childbearing potential should avoid becoming pregnant during treatment with belinostat. Advise pregnant women of the potential hazard to the fetus.

Breast-feeding

No information is available regarding the presence of belinostat in human milk, the effects on the breastfed child, or the effects on milk production. Due to the potential for serious adverse reactions in the nursing child, breastfeeding is not recommended during therapy or for 2 weeks after the last belinostat dose.

How should this medicine be used?

Belinostat comes as a powder to be mixed with liquid to be injected intravenously (into a vein) by a doctor or nurse in a hospital or clinic. It is usually given over a period of 30 minutes once daily on days 1 to 5 of a 21-day cycle. The length of your treatment depends on how well your body responds to the medication and the side effects that you experience.

Your doctor may need to adjust your dose or stop your treatment if you experience certain side effects. Be sure to tell your doctor how you are feeling during your treatment with the belinostat injection.

What special precautions should I follow?

Before receiving a belinostat injection,

  • tell your doctor and pharmacist if you are allergic to belinostat injection, any other medications, or any of the ingredients in belinostat injection. Ask your pharmacist for a list of the ingredients.
  • tell your doctor and pharmacist what other prescription and nonprescription medications, vitamins, nutritional supplements, and herbal products you are taking or plan to take or use while receiving belinostat injections. Your doctor may need to change the doses of your medications or monitor you carefully for side effects.
  • tell your doctor if you have previously received treatment with other chemotherapy medications, if you have or think you may have any type of infection now, or if you have nausea, vomiting, or diarrhea. Also, tell your doctor if you have or have ever had kidney or liver disease.
  • tell your doctor if you are pregnant, plan to become pregnant, or if you plan on fathering a child. You should not become pregnant while you are receiving belinostat injection. If you are female, you will need to take a pregnancy test before you start treatment and use birth control to prevent pregnancy during your treatment and for 6 months after your final dose. If you are a male, you and your partner should use birth control during your treatment with belinostat and for 3 months after your final dose. Talk to your doctor about birth control methods that you can use during your treatment. If you or your partner become pregnant while receiving a belinostat injection, call your doctor immediately. Belinostat injection may harm the fetus.
  • tell your doctor if you are breastfeeding. You should not breastfeed while you are receiving a belinostat injection and for 2 weeks after the final dose.
  • you should know that this medication may decrease fertility in men. Talk to your doctor about the risks of receiving a belinostat injection.
  • if you are having surgery, including dental surgery, tell the doctor or dentist that you are receiving a belinostat injection.

When to Contact Your Doctor or Health Care Provider:

  • Nausea (interferes with the ability to eat and is unrelieved with prescribed medication)
  • Vomiting (vomiting more than 4-5 times in a 24-hour period)
  • Constipation is unrelieved by laxative use.
  • Diarrhea (4-6 episodes in a 24-hour period)
  • Swelling of the feet or ankles. Sudden weight gain.
  • Unable to urinate for more than 8 hours
  • Unusual bleeding or bruising
  • Black or tarry stools, or blood in your stools
  • Blood in the urine
  • Pain or burning with urination
  • Extreme fatigue (unable to carry on self-care activities)
  • Unable to eat or drink for 24 hours or have signs of dehydration: tiredness, thirst, dry mouth, dark and decreased amount of urine, or dizziness.

Always inform your healthcare provider if you experience any unusual symptoms.

  • Before starting belinostat treatment, make sure you tell your doctor about any other medications you are taking (including prescription, over-the-counter, vitamins, herbal remedies, etc.). Do not take aspirin, or products containing aspirin unless your doctor specifically permits this.
  • Please inform your doctor and dentist before local anesthetic or vasoconstrictor medications are used (for example, epinephrine, mepivacaine, and levonordefrin).
  • Do not receive any kind of immunization or vaccination without your doctor’s approval while taking a belinostat.
  • Inform your doctor if you are aware of having a homozygous UGT1A1*28 allele (a gene variance/mutation) as it may require a dose adjustment of the belinostat.
  • Inform your healthcare professional if you are pregnant or may be pregnant prior to starting this treatment. Pregnancy category D (Belinostat may be hazardous to the fetus. Women who are pregnant or become pregnant must be advised of the potential hazard to the fetus.)
  • For both men and women: Use contraceptives, and do not conceive a child (get pregnant) while taking belinostat. Barrier methods of contraception, such as condoms, are recommended.
  • Do not breastfeed while taking a belinostat.

Self-Care Tips

  • Drink at least two to three quarts of fluid every 24 hours, unless you are instructed otherwise.
  • You may be at risk of infection so try to avoid crowds or people with colds, and report fever or any other signs of infection immediately to your healthcare provider.
  • Wash your hands often.
  • Use an electric razor and a soft toothbrush to minimize bleeding.
  • Avoid contact sports or activities that could cause injury.
  • To reduce nausea, take anti-nausea medications as prescribed by your doctor, and eat small, frequent meals.
  • Avoid sun exposure. Wear SPF 15 (or higher) sunblock and protective clothing.
  • In general, drinking alcoholic beverages should be kept to a minimum or avoided completely. You should discuss this with your doctor.
  • Get plenty of rest.
  • Maintain good nutrition.
  • Remain active as you are able. Gentle exercise is encouraged such as a daily walk.
  • If you experience symptoms or side effects, be sure to discuss them with your health care team. They can prescribe medications and/or offer other suggestions that are effective in managing such problems.

References

Doctor visit helper

Prepare before seeing a doctor

A simple rural-patient checklist to help you explain symptoms clearly, ask better questions, and avoid unsafe self-treatment.

Safety note: This is not a prescription or diagnosis. For severe symptoms, pregnancy danger signs, children with serious illness, chest pain, breathing difficulty, stroke-like weakness, or major injury, seek urgent care.

Which doctor may help?

Start with a registered doctor or the nearest qualified health center.

What to tell the doctor

  • Write when the problem started and how it changed.
  • Bring old prescriptions, investigation reports, and current medicines.
  • Write allergies, pregnancy status, diabetes, kidney/liver disease, and major past illnesses.
  • Bring one family member if the patient is weak, elderly, confused, or a child.

Questions to ask

  • What is the most likely cause of my symptoms?
  • Which danger signs mean I should go to hospital quickly?
  • Which tests are necessary now, and which can wait?
  • How should I take medicines safely and what side effects should I watch for?
  • When should I come for follow-up?

Tests to discuss

  • Vital signs: temperature, pulse, blood pressure, oxygen saturation
  • Basic physical examination by a clinician
  • CBC, urine test, blood sugar, or imaging only when clinically needed

Avoid these mistakes

  • Do not use antibiotics, steroid tablets/injections, or strong painkillers without proper medical advice.
  • Do not hide pregnancy, kidney disease, ulcer, allergy, or blood thinner use.
  • Do not delay emergency care when danger signs are present.

Medicine safety and first-aid guide

This section is for patient education only. It does not replace a doctor, pharmacist, or emergency care.

Safe first steps

  • Avoid heavy lifting, sudden bending, and prolonged bed rest.
  • Use comfortable posture and gentle movement as tolerated.
  • Discuss physiotherapy, X-ray, or MRI only when clinically needed.

OTC medicine safety

  • For mild back pain, pain-relief medicine may be discussed with a doctor or pharmacist.
  • Avoid repeated painkiller use if you have kidney disease, stomach ulcer, uncontrolled blood pressure, or are taking blood thinners.

Avoid these mistakes

  • Do not start antibiotics without a proper medical decision.
  • Do not use steroid tablets or injections casually for quick relief.
  • Do not delay emergency care because of home remedies.

Get urgent help if

  • Back pain with leg weakness, numbness around private area, loss of urine/stool control, fever, cancer history, or major injury needs urgent care.
Medicine names, dose, and timing must be decided by a qualified clinician or pharmacist after checking age, pregnancy, allergy, other diseases, and current medicines.

For rural patients and family caregivers

Patient health record and symptom diary

Write your symptoms, medicines already taken, test results, and questions before visiting a doctor. This note stays on your device unless you print or copy it.

Doctor to discuss: Medicine doctor / pediatrician for children / qualified clinician
Tests to discuss with doctor
  • Temperature chart and hydration assessment
  • CBC with platelet count if fever persists or dengue/other infection is possible
  • Urine test, malaria/dengue tests, chest evaluation, or blood culture only when clinically indicated
Questions to ask
  • What is the most likely cause of my symptoms?
  • Which warning signs mean I should go to emergency care?
  • Which tests are really needed now?
  • Which medicines are safe for my age, pregnancy status, allergy, kidney/liver/stomach condition, and current medicines?
  • Do I need antibiotics, or is this more likely viral?

Emergency warning signs such as chest pain, severe breathing difficulty, sudden weakness, confusion, severe dehydration, major injury, or loss of bladder/bowel control need urgent medical care. Do not wait for online information.

Safe pathway to proper treatment

Care roadmap for: Belinostat – Uses, Dosage, Side Effects, Interactions

Use this simple roadmap to understand the next safe steps. It is educational and does not replace examination by a doctor.

Go to emergency care if you notice:
  • Severe or rapidly worsening symptoms
  • Breathing difficulty, chest pain, fainting, confusion, severe weakness, major injury, or severe dehydration
Doctor / service to discuss: Qualified healthcare provider; specialist depends on symptoms and examination.
  1. Step 1

    Check danger signs first

    If danger signs are present, seek emergency care and do not wait for online information.

  2. Step 2

    Record the symptom story

    Write when symptoms started, severity, medicines already taken, allergies, pregnancy status, and test results.

  3. Step 3

    Visit a qualified clinician

    A doctor, nurse, or qualified healthcare provider can examine you and decide which tests or treatment are needed.

  4. Step 4

    Do only useful tests

    Do tests after clinical assessment. Avoid unnecessary tests, random antibiotics, or repeated medicines without diagnosis.

  5. Step 5

    Follow up and return early if worse

    If symptoms worsen, new warning signs appear, or treatment is not helping, return for review quickly.

Rural patient practical tips
  • Take a written symptom diary and all previous prescriptions/test reports.
  • Do not hide medicines already taken, even herbal or over-the-counter medicines.
  • Ask which warning signs mean urgent referral to hospital.

This roadmap is for education. A real diagnosis and treatment plan requires history, examination, and clinical judgment.

RX Patient Help

Ask a health question safely

Write your symptom story. A health professional or site editor can review it before any answer is prepared. This box is not for emergency care.

Emergency first: Severe chest pain, breathing trouble, unconsciousness, stroke signs, severe injury, heavy bleeding, or rapidly worsening symptoms need urgent local medical care now.

Frequently Asked Questions

Mechanism of Action Belinostat inhibits the activity of histone deacetylase (HDAC) thus preventing the removal of acetyl groups from the lysine residues of histones and some non-histone proteins. In vitro, belinostat caused the accumulation of acetylated histones and other proteins and increased the expression of tumor-suppressor genes. It ultimately induces cell cycle arrest, inhibition of angiogenesis, and/or apoptosis of some transformed cells. Beleodaq is a histone deacetylase (HDAC) inhibitor that exhibits pan-HDAC inhibition and potent growth inhibitory and pro-apoptotic activities in a variety of tumor cells, including PTCL cells, at nanomolar concentrations. None of the trials show any clinically relevant changes caused by Beleodaq on heart rate, PR duration, or QRS duration as measures of autonomic state, atrioventricular conduction or depolarization; there were no cases of Torsades de Pointes. Indications Belinostat is indicated for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL) with a manageable safety profile. It is a potential alternative therapy for patients who did not experience adequate response to first-line drugs for PTCL. It can be used in patients with baseline thrombocytopenia. Belinostat is an intravenously administered histone deacetylase inhibitor and antineoplastic agent that is approved for use in refractory or relapsed peripheral T-cell lymphoma. Belinostat is associated with a moderate rate of minor serum enzyme elevations during therapy and has been reported to cause clinically apparent fatal, acute liver injury. Relapsed or refractory peripheral T-cell lymphoma Use in Cancer Belinostat is approved to treat: Peripheral T-cell lymphoma in patients whose disease has recurred (come back) or is refractory (does not respond to treatment). This use is approved under FDA’s Accelerated Approval Program. As a condition of approval, a confirmatory trial(s) must show that belinostat provides a clinical benefit in these patients. Belinostat is also being studied in the treatment of other types of cancer. Contraindications Anemia, bone marrow suppression, leukopenia, neutropenia, thrombocytopenia - Hematologic toxicity, including thrombocytopenia, leukopenia (neutropenia and lymphopenia), and anemia have been reported with belinostat therapy. Monitor complete blood cell counts prior to starting therapy and then weekly. Dose modifications may be necessary in patients with bone marrow suppression and should be determined by the absolute neutrophil count (ANC) and platelet count nadirs of the previous cycle of therapy. Platelet counts should be >= 50,000/mm3 and ANC > 1000/mm3 before starting each cycle. Chemotherapy, infection, sepsis - Serious infections, including pneumonia and sepsis, have occurred during treatment with belinostat; some occurrences have been fatal. Do not administer belinostat to patients with an active infection. Use caution in patients with a history of extensive or intensive chemotherapy, as they may be at higher risk of life-threatening infections. Hepatic disease - Abnormal liver function tests and fatal hepatic toxicity have been observed in patients receiving belinostat. Monitor liver function tests prior to the start of each cycle of therapy. Patients with signs of hepatic impairment or hepatic disease may require dose modification or discontinuation. Tumor lysis syndrome (TLS) - Tumor lysis syndrome (TLS) has occurred in patients treated with belinostat. Patients with high tumor burden or advanced-stage disease are at greater risk for developing TLS; consider tumor lysis prophylaxis with anti-hyperuricemic agents and hydration beginning 12—24 hours prior to treatment with belinostat in these patients. For TLS treatment, administer aggressive intravenous hydration and antihyperuricemic agents, correct electrolyte abnormalities, and monitor renal function. Dosage Strengths: 500 mg Lymphoma 1,000 mg/m2 IV over 30 minutes once daily on days 1 to 5 of a 21-day cycle Duration of therapy: Repeat the cycle every 21 days until disease progression or unacceptable toxicity. Dose reduction, discontinuation, or interruption of therapy may be needed to manage adverse reactions. Dose Adjustments Hematologic toxicities: Nadir absolute neutrophil count less than 0.5 x 10(9)/L or platelet count less than 25 x 10(9)/L: Decrease dose by 25% (750 mg/m2) Non-hematologic toxicities: Any Grade 3 or 4 adverse reaction: Decrease dose by 25% (750 mg/m2) Recurrence of Grade 3 or 4 adverse reaction after 2 dose reductions: Discontinue treatment Patients with Reduced UGT1A1 Activity: Reduce the starting dose to 750 mg/m2 in patients known to be homozygous for the UGT1A1*28 allele. Side Effects The Most Common nausea diarrhea vomiting constipation headache tiredness decreased appetite pain at the injection site swelling of the hands, feet, or ankles rash fever, cough, chills, muscle aches, worsening skin problems, flu-like symptoms, or other signs of infection painful, frequent, burning or difficult urination unusual bleeding or bruising dizziness, weakness, excessive tiredness, pale skin, or shortness of breath yellowing of the skin or eyes, pain in the right upper stomach area, dark urine, or itching More Common severe ongoing nausea, vomiting, or diarrhea; a fever, chills, muscle aches, flu-like symptoms, cough with mucus, chest pain, fast heartbeats, rapid breathing or shortness of breath; easy bruising, unusual bleeding, purple or red spots under your skin; pain or burning when you urinate; confusion, severe drowsiness, feeling very ill; liver problems--loss of appetite, stomach pain (upper right side), tiredness, itching, dark urine, clay-colored stools, jaundice (yellowing of the skin or eyes); low red blood cells (anemia)--pale skin, unusual tiredness, feeling light-headed or short of breath, cold hands and feet; or signs of tumor cell breakdown--tiredness, weakness, muscle cramps, nausea, vomiting, diarrhea, fast or slow heart rate, tingling in your hands and feet or around your mouth. Rare chest pain confusion cough decreased urine dizziness, faintness, or lightheadedness when getting up suddenly from a lying or sitting position dry mouth fainting fast heartbeat fever or chills increased thirst irregular heartbeat loss of appetite mood changes muscle pain or cramps nausea or vomiting numbness or tingling in the hands, feet, or lips pale skin pinpoint red spots on the skin rapid, shallow breathing sore throat sweating tenderness tightness in the chest troubled breathing with exertion unusual bleeding or bruising unusual tiredness or weakness unusual weight gain or loss Drug Interaction DRUG INTERACTION Abatacept The risk or severity of adverse effects can be increased when Abatacept is combined with Belinostat. Abciximab The risk or severity of bleeding can be increased when Abciximab is combined with Belinostat. Abemaciclib The serum concentration of Abemaciclib can be increased when it is combined with Belinostat. Abrocitinib The serum concentration of Belinostat can be increased when it is combined with Abrocitinib. Acenocoumarol The metabolism of Acenocoumarol can be increased when combined with Belinostat. Acetaminophen The metabolism of Acetaminophen can be increased when combined with Belinostat. Acetylsalicylic acid The risk or severity of bleeding can be increased when Acetylsalicylic acid is combined with Belinostat. Acyclovir The metabolism of Acyclovir can be increased when combined with Belinostat. Adalimumab The risk or severity of adverse effects can be increased when Adalimumab is combined with Belinostat. Adenine The metabolism of Belinostat can be decreased when combined with Adenine. Adenovirus type 7 vaccine live The risk or severity of infection can be increased when Adenovirus type 7 vaccine live is combined with Belinostat. Afatinib The serum concentration of Belinostat can be increased when it is combined with Afatinib. Agomelatine The metabolism of Agomelatine can be increased when combined with Belinostat. Albendazole The metabolism of Albendazole can be increased when combined with Belinostat. Aldesleukin The risk or severity of adverse effects can be increased when Aldesleukin is combined with Belinostat. Alefacept The risk or severity of adverse effects can be increased when Alefacept is combined with Belinostat. Alemtuzumab The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Belinostat. Allogeneic thymus tissue The therapeutic efficacy of Allogeneic processed thymus tissue can be decreased when used in combination with Belinostat. Allopurinol The risk or severity of adverse effects can be increased when Allopurinol is combined with Belinostat. Alosetron The metabolism of Alosetron can be increased when combined with Belinostat. Alteplase The risk or severity of bleeding can be increased when Alteplase is combined with Belinostat. Altretamine The risk or severity of adverse effects can be increased when Altretamine is combined with Belinostat. Ambrisentan The serum concentration of Ambrisentan can be increased when it is combined with Belinostat. Aminophenazone The metabolism of Aminophenazone can be increased when combined with Belinostat. Aminophylline The metabolism of Aminophylline can be increased when combined with Belinostat. Amiodarone The serum concentration of Belinostat can be increased when it is combined with Amiodarone. Amitriptyline The metabolism of Belinostat can be decreased when combined with Amitriptyline. Amsacrine The risk or severity of adverse effects can be increased when Amsacrine is combined with Belinostat. Anagrelide The metabolism of Anagrelide can be increased when combined with Belinostat. Anakinra The risk or severity of adverse effects can be increased when Anakinra is combined with Belinostat. Ancrod The risk or severity of bleeding can be increased when Ancrod is combined with Belinostat. Anifrolumab The risk or severity of adverse effects can be increased when Belinostat is combined with Anifrolumab. Anistreplase The risk or severity of bleeding can be increased when Anistreplase is combined with Belinostat. Anthrax immune globulin The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Belinostat. Anthrax vaccine The risk or severity of infection can be increased when Anthrax vaccine is combined with Belinostat. antilymphocyte immunoglobulin The risk or severity of adverse effects can be increased when Belinostat is combined with Antilymphocyte immunoglobulin (horse). Antipyrine The metabolism of Antipyrine can be increased when combined with Belinostat. Antithrombin Alfa The risk or severity of bleeding can be increased when Antithrombin Alfa is combined with Belinostat. Antithrombin III human The risk or severity of bleeding can be increased when Antithrombin III human is combined with Belinostat. Antithymocyte immunoglobulin The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Belinostat. Apalutamide The serum concentration of Belinostat can be decreased when it is combined with Apalutamide. Apixaban The serum concentration of Apixaban can be increased when it is combined with Belinostat. Apremilast The risk or severity of adverse effects can be increased when Belinostat is combined with Apremilast. Ardeparin The risk or severity of bleeding can be increased when Ardeparin is combined with Belinostat. Argatroban The risk or severity of bleeding can be increased when Argatroban is combined with Belinostat. Arsenic trioxide The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Belinostat. Articaine The risk or severity of methemoglobinemia can be increased when Belinostat is combined with Articaine. Asciminib The serum concentration of Belinostat can be increased when it is combined with Asciminib. Asenapine The metabolism of Asenapine can be increased when combined with Belinostat. COVID-19 Vaccine The therapeutic efficacy of AstraZeneca COVID-19 Vaccine can be decreased when used in combination with Belinostat. Asunaprevir The serum concentration of Belinostat can be increased when it is combined with Asunaprevir. Atazanavir The metabolism of Belinostat can be decreased when combined with Atazanavir. Avanafil The serum concentration of Avanafil can be increased when it is combined with Belinostat. Avatrombopag The serum concentration of Avatrombopag can be increased when it is combined with Belinostat. Axitinib The metabolism of Axitinib can be increased when combined with Belinostat. Azacitidine The risk or severity of adverse effects can be increased when Azacitidine is combined with Belinostat. Azathioprine The risk or severity of adverse effects can be increased when Azathioprine is combined with Belinostat. Azelastine The metabolism of Azelastine can be increased when combined with Belinostat. Bacillusantigen The risk or severity of infection can be increased when Bacillus calmette-guerin substrain connaught live antigen is combined with Belinostat. BCG-I live antigen The therapeutic efficacy of Bacillus calmette-guerin substrain russian BCG-I live antigen can be decreased when used in combination with Belinostat. Bacillus The risk or severity of infection can be increased when Bacillus calmette-guerin substrain tice live antigen is combined with Belinostat. Baricitinib The risk or severity of adverse effects can be increased when Belinostat is combined with Baricitinib. Basiliximab The risk or severity of adverse effects can be increased when Basiliximab is combined with Belinostat. BCG vaccine The risk or severity of infection can be increased when BCG vaccine is combined with Belinostat. Beclomethasone dipropionate The risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Belinostat. Belantamab mafodotin The serum concentration of Belantamab mafodotin can be increased when it is combined with Belinostat. Belatacept The risk or severity of adverse effects can be increased when Belinostat is combined with Belatacept. Belimumab The risk or severity of adverse effects can be increased when Belinostat is combined with Belimumab. Belumosudil The risk or severity of adverse effects can be increased when Belinostat is combined with Belumosudil. Bemiparin The risk or severity of bleeding can be increased when Bemiparin is combined with Belinostat. Bendamustine The risk or severity of adverse effects can be increased when Belinostat is combined with Bendamustine. Bendroflumethiazide The risk or severity of neutropenia and thrombocytopenia can be increased when Bendroflumethiazide is combined with Belinostat. Benzocaine The risk or severity of methemoglobinemia can be increased when Belinostat is combined with Benzocaine. Benzthiazide The risk or severity of neutropenia and thrombocytopenia can be increased when Benzthiazide is combined with Belinostat. Benzyl alcohol The risk or severity of methemoglobinemia can be increased when Belinostat is combined with Benzyl alcohol. Berotralstat The serum concentration of Berotralstat can be increased when it is combined with Belinostat. Betamethasone The risk or severity of adverse effects can be increased when Betamethasone is combined with Belinostat. Betaxolol The metabolism of Betaxolol can be increased when combined with Belinostat. Betrixaban The serum concentration of Betrixaban can be increased when it is combined with Belinostat. Bexarotene The risk or severity of adverse effects can be increased when Bexarotene is combined with Belinostat. Bimekizumab The risk or severity of adverse effects can be increased when Belinostat is combined with Bimekizumab. Binimetinib The serum concentration of Binimetinib can be increased when it is combined with Belinostat. Bisoprolol The serum concentration of Belinostat can be increased when it is combined with Bisoprolol. Bivalirudin The risk or severity of bleeding can be increased when Bivalirudin is combined with Belinostat. Bleomycin The risk or severity of adverse effects can be increased when Bleomycin is combined with Belinostat. Blinatumomab The risk or severity of adverse effects can be increased when Belinostat is combined with Blinatumomab. Bordetella pertussis The therapeutic efficacy of Bordetella pertussis toxoid antigen (formaldehyde, glutaraldehyde inactivated) can be decreased when used in combination with Belinostat. Bortezomib The risk or severity of adverse effects can be increased when Bortezomib is combined with Belinostat. Bosutinib The risk or severity of adverse effects can be increased when Belinostat is combined with Bosutinib. Brentuximab vedotin The risk or severity of adverse effects can be increased when Belinostat is combined with Brentuximab vedotin. Brodalumab The risk or severity of adverse effects can be increased when Belinostat is combined with Brodalumab. Bromazepam The metabolism of Bromazepam can be increased when combined with Belinostat. Bromotheophylline The metabolism of Bromotheophylline can be increased when combined with Belinostat. Budesonide The risk or severity of adverse effects can be increased when Budesonide is combined with Belinostat. Bupivacaine The risk or severity of methemoglobinemia can be increased when Belinostat is combined with Bupivacaine. Busulfan The risk or severity of adverse effects can be increased when Busulfan is combined with Belinostat. Butacaine The risk or severity of methemoglobinemia can be increased when Belinostat is combined with Butacaine. Butamben The risk or severity of methemoglobinemia can be increased when Belinostat is combined with Butamben. Cabazitaxel The risk or severity of adverse effects can be increased when Belinostat is combined with Cabazitaxel. Cabergoline The serum concentration of Cabergoline can be increased when it is combined with Belinostat. Canagliflozin The serum concentration of Belinostat can be increased when it is combined with Canagliflozin. Canakinumab The risk or severity of adverse effects can be increased when Belinostat is combined with Canakinumab. Cangrelor The risk or severity of bleeding can be increased when Cangrelor is combined with Belinostat. Capecitabine The risk or severity of adverse effects can be increased when Capecitabine is combined with Belinostat. Caplacizumab The risk or severity of bleeding can be increased when Caplacizumab is combined with Belinostat. Capmatinib The serum concentration of Belinostat can be increased when it is combined with Capmatinib. Capsaicin The risk or severity of methemoglobinemia can be increased when Belinostat is combined with Capsaicin. Carbamazepine The metabolism of Belinostat can be increased when combined with Carbamazepine. Carboplatin The risk or severity of adverse effects can be increased when Carboplatin is combined with Belinostat. Carfilzomib The risk or severity of adverse effects can be increased when Belinostat is combined with Carfilzomib. Carmustine The risk or severity of adverse effects can be increased when Carmustine is combined with Belinostat. Carvedilol The serum concentration of Belinostat can be increased when it is combined with Carvedilol. Ceritinib The serum concentration of Ceritinib can be increased when it is combined with Belinostat. Certolizumab pegol The risk or severity of adverse effects can be increased when Belinostat is combined with Certolizumab pegol. Chlorambucil The risk or severity of adverse effects can be increased when Chlorambucil is combined with Belinostat. Chloramphenicol The risk or severity of adverse effects can be increased when Chloramphenicol is combined with Belinostat. Chloroprocaine The risk or severity of methemoglobinemia can be increased when Belinostat is combined with Chloroprocaine. Chlorothiazide The risk or severity of neutropenia and thrombocytopenia can be increased when Chlorothiazide is combined with Belinostat. Chlorpromazine The metabolism of Chlorpromazine can be increased when combined with Belinostat. Chlorzoxazone The metabolism of Chlorzoxazone can be increased when combined with Belinostat. Ciclesonide The risk or severity of adverse effects can be increased when Ciclesonide is combined with Belinostat. Cilostazol The risk or severity of bleeding can be increased when Cilostazol is combined with Belinostat. Cinacalcet The metabolism of Cinacalcet can be increased when combined with Belinostat. Cinchocaine The risk or severity of methemoglobinemia can be increased when Belinostat is combined with Cinchocaine. Cinnarizine The metabolism of Cinnarizine can be increased when combined with Belinostat. Cisplatin The risk or severity of adverse effects can be increased when Cisplatin is combined with Belinostat. Cladribine The risk or severity of adverse effects can be increased when Cladribine is combined with Belinostat. Clarithromycin The serum concentration of Belinostat can be increased when it is combined with Clarithromycin. Clobazam The serum concentration of Belinostat can be increased when it is combined with Clobazam. Clobetasol propionate The risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Belinostat. Clofarabine The risk or severity of adverse effects can be increased when Clofarabine is combined with Belinostat. Clofazimine The serum concentration of Belinostat can be increased when it is combined with Clofazimine. Clomifene The serum concentration of Belinostat can be increased when it is combined with Clomifene. Clomipramine The metabolism of Clomipramine can be increased when combined with Belinostat. Clonidine The metabolism of Clonidine can be increased when combined with Belinostat. Clopidogrel The risk or severity of bleeding can be increased when Clopidogrel is combined with Belinostat. Clostridium The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Belinostat. Clozapine The risk or severity of neutropenia can be increased when Belinostat is combined with Clozapine. Cobicistat The serum concentration of Belinostat can be increased when it is combined with Cobicistat. Cobimetinib The serum concentration of Cobimetinib can be increased when it is combined with Belinostat. Cocaine The risk or severity of methemoglobinemia can be increased when Belinostat is combined with Cocaine. Colchicine The serum concentration of Belinostat can be increased when it is combined with Colchicine. Conivaptan The serum concentration of Belinostat can be increased when it is combined with Conivaptan. Conjugated estrogens The metabolism of Conjugated estrogens can be increased when combined with Belinostat. Copanlisib The serum concentration of Copanlisib can be increased when it is combined with Belinostat. Corticotropin The risk or severity of adverse effects can be increased when Corticotropin is combined with Belinostat. Cortisone acetate The risk or severity of adverse effects can be increased when Cortisone acetate is combined with Belinostat. Corynebacterium The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Belinostat. Crizotinib The serum concentration of Belinostat can be increased when it is combined with Crizotinib. Curcumin The serum concentration of Belinostat can be increased when it is combined with Curcumin. Cyanocobalamin The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Belinostat. Cyclobenzaprine The metabolism of Cyclobenzaprine can be increased when combined with Belinostat. Cyclopenthiazide The risk or severity of neutropenia and thrombocytopenia can be increased when Cyclopenthiazide is combined with Belinostat. Cyclophosphamide The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Belinostat. Cyclosporine Belinostat may increase the immunosuppressive activities of Cyclosporine. Cyclothiazide The risk or severity of neutropenia and thrombocytopenia can be increased when Cyclothiazide is combined with Belinostat. Cytarabine The risk or severity of adverse effects can be increased when Cytarabine is combined with Belinostat. Dabigatran The risk or severity of bleeding can be increased when Dabigatran is combined with Belinostat. Dabigatran etexilate The serum concentration of Dabigatran etexilate can be increased when it is combined with Belinostat. Dabrafenib The metabolism of Belinostat can be decreased when combined with Dabrafenib. Dacarbazine The risk or severity of adverse effects can be increased when Dacarbazine is combined with Belinostat. Daclatasvir The serum concentration of Belinostat can be increased when it is combined with Daclatasvir. Dacomitinib The metabolism of Belinostat can be decreased when combined with Dacomitinib. Dactinomycin The risk or severity of adverse effects can be increased when Dactinomycin is combined with Belinostat. Dalteparin The risk or severity of bleeding can be increased when Dalteparin is combined with Belinostat. Danaparoid The risk or severity of bleeding can be increased when Danaparoid is combined with Belinostat. Dapagliflozin The metabolism of Dapagliflozin can be increased when combined with Belinostat. Daptomycin The serum concentration of Belinostat can be increased when it is combined with Daptomycin. Darbepoetin alfa The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Belinostat. Darolutamide The serum concentration of Darolutamide can be increased when it is combined with Belinostat. Darunavir The serum concentration of Belinostat can be increased when it is combined with Darunavir. Dasabuvir The metabolism of Belinostat can be decreased when combined with Dasabuvir. Dasatinib The risk or severity of adverse effects can be increased when Dasatinib is combined with Belinostat. Daunorubicin The risk or severity of adverse effects can be increased when Daunorubicin is combined with Belinostat. Decitabine The risk or severity of adverse effects can be increased when Decitabine is combined with Belinostat. Deferasirox The metabolism of Belinostat can be decreased when combined with Deferasirox. Defibrotide The risk or severity of bleeding can be increased when Defibrotide is combined with Belinostat. Deflazacort The risk or severity of adverse effects can be increased when Belinostat is combined with Deflazacort. Denosumab The risk or severity of adverse effects can be increased when Denosumab is combined with Belinostat. Desirudin The risk or severity of bleeding can be increased when Desirudin is combined with Belinostat. Desogestrel The metabolism of Belinostat can be increased when combined with Desogestrel. Desoximetasone The risk or severity of adverse effects can be increased when Desoximetasone is combined with Belinostat. Deucravacitinib The risk or severity of adverse effects can be increased when Belinostat is combined with Deucravacitinib. Dexamethasone The risk or severity of adverse effects can be increased when Dexamethasone is combined with Belinostat. Dexfenfluramine The metabolism of Dexfenfluramine can be increased when combined with Belinostat. Dexrazoxane The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Belinostat. Dextran The risk or severity of bleeding can be increased when Dextran is combined with Belinostat. Diclofenac The metabolism of Diclofenac can be increased when combined with Belinostat. Dicoumarol The risk or severity of bleeding can be increased when Dicoumarol is combined with Belinostat. Difluocortolone The risk or severity of adverse effects can be increased when Belinostat is combined with Difluocortolone. Digitoxin The serum concentration of Digitoxin can be increased when it is combined with Belinostat. Digoxin The serum concentration of Digoxin can be increased when it is combined with Belinostat. Dihydralazine The metabolism of Dihydralazine can be increased when combined with Belinostat. Dimethyl fumarate The risk or severity of adverse effects can be increased when Belinostat is combined with Dimethyl fumarate. Dinutuximab The risk or severity of adverse effects can be increased when Belinostat is combined with Dinutuximab. Diosmin The serum concentration of Belinostat can be increased when it is combined with Diosmin. Diphenhydramine The risk or severity of methemoglobinemia can be increased when Belinostat is combined with Diphenhydramine. Dipyridamole The risk or severity of bleeding can be increased when Dipyridamole is combined with Belinostat. Diroximel fumarate The risk or severity of adverse effects can be increased when Belinostat is combined with Diroximel fumarate. Domperidone The metabolism of Domperidone can be increased when combined with Belinostat. Doxepin The metabolism of Doxepin can be increased when combined with Belinostat. Doxorubicin The risk or severity of adverse effects can be increased when Doxorubicin is combined with Belinostat. Dronedarone The serum concentration of Belinostat can be increased when it is combined with Dronedarone. Drotrecogin alfa The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Belinostat. Duvelisib The serum concentration of Duvelisib can be increased when it is combined with Belinostat. Dyclonine The risk or severity of methemoglobinemia can be increased when Belinostat is combined with Dyclonine. Ebola Zaire vaccine The therapeutic efficacy of Ebola Zaire vaccine (live, attenuated) can be decreased when used in combination with Belinostat. Eculizumab The risk or severity of adverse effects can be increased when Eculizumab is combined with Belinostat. Edetic acid The risk or severity of bleeding can be increased when Edetic acid is combined with Belinostat. Edoxaban The serum concentration of Edoxaban can be increased when it is combined with Belinostat. Efalizumab The risk or severity of adverse effects can be increased when Efalizumab is combined with Belinostat. Efavirenz The metabolism of Belinostat can be increased when combined with Efavirenz. Elagolix The serum concentration of Belinostat can be increased when it is combined with Elagolix. Elbasvir The serum concentration of Elbasvir can be increased when it is combined with Belinostat. Eliglustat The serum concentration of Belinostat can be increased when it is combined with Eliglustat. Eltrombopag The metabolism of Belinostat can be decreased when combined with Eltrombopag. Emapalumab The risk or severity of adverse effects can be increased when Belinostat is combined with Emapalumab. Enasidenib The metabolism of Belinostat can be decreased when combined with Enasidenib. Enfortumab vedotin The serum concentration of Enfortumab vedotin can be increased when it is combined with Belinostat. Enoxaparin The risk or severity of bleeding can be increased when Enoxaparin is combined with Belinostat. Entecavir The metabolism of Entecavir can be increased when combined with Belinostat. Entrectinib The serum concentration of Belinostat can be increased when it is combined with Entrectinib. Epirubicin The risk or severity of adverse effects can be increased when Epirubicin is combined with Belinostat. Epoprostenol The risk or severity of bleeding can be increased when Epoprostenol is combined with Belinostat. Eptifibatide The risk or severity of bleeding can be increased when Eptifibatide is combined with Belinostat. Erdafitinib The serum concentration of Belinostat can be increased when it is combined with Erdafitinib. Eribulin The risk or severity of adverse effects can be increased when Belinostat is combined with Eribulin. Erlotinib The metabolism of Belinostat can be decreased when combined with Erlotinib. Ertugliflozin The metabolism of Belinostat can be decreased when combined with Ertugliflozin. Erythromycin The serum concentration of Belinostat can be increased when it is combined with Erythromycin. Erythropoietin The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Belinostat. Estradiol The metabolism of Estradiol can be increased when combined with Belinostat. Estradiol acetate The metabolism of Estradiol acetate can be increased when combined with Belinostat. Estradiol benzoate The metabolism of Estradiol benzoate can be increased when combined with Belinostat. Estradiol cypionate The metabolism of Estradiol cypionate can be increased when combined with Belinostat. Estradiol dienanthate The metabolism of Estradiol dienanthate can be increased when combined with Belinostat. Estradiol valerate The metabolism of Estradiol valerate can be increased when combined with Belinostat. Estramustine The risk or severity of adverse effects can be increased when Estramustine is combined with Belinostat. Estrone sulfate The metabolism of Estrone sulfate can be increased when combined with Belinostat. Etanercept The risk or severity of adverse effects can be increased when Etanercept is combined with Belinostat. Ethanol The metabolism of Ethanol can be increased when combined with Belinostat. Ethinylestradiol The metabolism of Belinostat can be increased when combined with Ethinylestradiol. Ethyl chloride The risk or severity of methemoglobinemia can be increased when Belinostat is combined with Ethyl chloride. Etidocaine The risk or severity of methemoglobinemia can be increased when Belinostat is combined with Etidocaine. Etoposide The risk or severity of adverse effects can be increased when Etoposide is combined with Belinostat. Etoricoxib The metabolism of Etoricoxib can be increased when combined with Belinostat. Everolimus The risk or severity of adverse effects can be increased when Everolimus is combined with Belinostat. Favipiravir The serum concentration of Belinostat can be increased when it is combined with Favipiravir. Fedratinib The serum concentration of Belinostat can be increased when it is combined with Fedratinib. Fenfluramine The metabolism of Fenfluramine can be increased when combined with Belinostat. Fexinidazole The metabolism of Fexinidazole can be increased when combined with Belinostat. Fexofenadine The serum concentration of Belinostat can be increased when it is combined with Fexofenadine. Filgotinib The risk or severity of adverse effects can be increased when Belinostat is combined with Filgotinib. Fingolimod Belinostat may increase the immunosuppressive activities of Fingolimod. Flecainide The metabolism of Flecainide can be increased when combined with Belinostat. Flibanserin The serum concentration of Belinostat can be increased when it is combined with Flibanserin. Floxuridine The risk or severity of adverse effects can be increased when Floxuridine is combined with Belinostat. Fluconazole The serum concentration of Belinostat can be increased when it is combined with Fluconazole. Flucytosine The risk or severity of adverse effects can be increased when Flucytosine is combined with Belinostat. Fludarabine The risk or severity of adverse effects can be increased when Fludarabine is combined with Belinostat. Fludrocortisone The risk or severity of adverse effects can be increased when Fludrocortisone is combined with Belinostat. Fluindione The risk or severity of bleeding can be increased when Fluindione is combined with Belinostat. Flunarizine The metabolism of Flunarizine can be increased when combined with Belinostat. Flunisolide The risk or severity of adverse effects can be increased when Flunisolide is combined with Belinostat. Flunitrazepam The metabolism of Belinostat can be decreased when combined with Flunitrazepam. Fluocinolone acetonide The risk or severity of adverse effects can be increased when Fluocinolone acetonide is combined with Belinostat. Fluocinonide The risk or severity of adverse effects can be increased when Fluocinonide is combined with Belinostat. Fluocortolone The risk or severity of adverse effects can be increased when Belinostat is combined with Fluocortolone. Fluorometholone The risk or severity of adverse effects can be increased when Fluorometholone is combined with Belinostat. Fluorouracil The risk or severity of adverse effects can be increased when Fluorouracil is combined with Belinostat. Fluoxetine The metabolism of Fluoxetine can be increased when combined with Belinostat. Flupentixol The risk or severity of myelosuppression can be increased when Flupentixol is combined with Belinostat. Fluprednisolone The risk or severity of adverse effects can be increased when Belinostat is combined with Fluprednisolone. Flurbiprofen The metabolism of Belinostat can be decreased when combined with Flurbiprofen. Flutamide The metabolism of Flutamide can be increased when combined with Belinostat. Fluticasone The risk or severity of adverse effects can be increased when Belinostat is combined with Fluticasone. Fluticasone furoate The risk or severity of adverse effects can be increased when Belinostat is combined with Fluticasone furoate. Fluticasone propionate The risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Belinostat. Fluvoxamine The metabolism of Fluvoxamine can be increased when combined with Belinostat. Fondaparinux The risk or severity of bleeding can be increased when Fondaparinux is combined with Belinostat. Fostamatinib The metabolism of Belinostat can be decreased when combined with Fostamatinib. Fostemsavir The serum concentration of Fostemsavir can be increased when it is combined with Belinostat. Frovatriptan The metabolism of Frovatriptan can be increased when combined with Belinostat. Futibatinib The serum concentration of Futibatinib can be increased when it is combined with Belinostat. Gallium nitrate The risk or severity of adverse effects can be increased when Belinostat is combined with Gallium nitrate. Gemcitabine The risk or severity of adverse effects can be increased when Gemcitabine is combined with Belinostat. Gemfibrozil The metabolism of Belinostat can be decreased when combined with Gemfibrozil. Gemtuzumab ozogamicin The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Belinostat. Gilteritinib The serum concentration of Gilteritinib can be increased when it is combined with Belinostat. Glasdegib The serum concentration of Belinostat can be increased when it is combined with Glasdegib. Glatiramer The risk or severity of adverse effects can be increased when Belinostat is combined with Glatiramer. Glecaprevir The metabolism of Belinostat can be decreased when combined with Glecaprevir. Golimumab The risk or severity of adverse effects can be increased when Belinostat is combined with Golimumab. Grazoprevir The serum concentration of Grazoprevir can be increased when it is combined with Belinostat. Grepafloxacin The metabolism of Grepafloxacin can be increased when combined with Belinostat. Guanabenz The metabolism of Guanabenz can be increased when combined with Belinostat. Ketoconazole The metabolism of Belinostat can be decreased when combined with Ketoconazole. Lamotrigine The metabolism of Belinostat can be increased when combined with Lamotrigine. Lapatinib The serum concentration of Belinostat can be increased when it is combined with Lapatinib. Larotrectinib The serum concentration of Larotrectinib can be increased when it is combined with Belinostat. Lasmiditan The serum concentration of Belinostat can be increased when it is combined with Lasmiditan. Ledipasvir The serum concentration of Belinostat can be increased when it is combined with Ledipasvir. Lefamulin The serum concentration of Lefamulin can be increased when it is combined with Belinostat. Leflunomide The risk or severity of adverse effects can be increased when Belinostat is combined with Leflunomide. Lemborexant The serum concentration of Lemborexant can be increased when it is combined with Belinostat. Lenalidomide The risk or severity of adverse effects can be increased when Lenalidomide is combined with Belinostat. Lenvatinib The serum concentration of Lenvatinib can be increased when it is combined with Belinostat. Lepirudin The risk or severity of bleeding can be increased when Lepirudin is combined with Belinostat. Levobupivacaine The risk or severity of methemoglobinemia can be increased when Belinostat is combined with Levobupivacaine. Levoketoconazole The serum concentration of Belinostat can be increased when it is combined with Levoketoconazole. Lidocaine The risk or severity of methemoglobinemia can be increased when Belinostat is combined with Lidocaine. Linagliptin The serum concentration of Belinostat can be increased when it is combined with Linagliptin. Linezolid The risk or severity of adverse effects can be increased when Linezolid is combined with Belinostat. Lipegfilgrastim Belinostat may increase the myelosuppressive activities of Lipegfilgrastim. Lofexidine The metabolism of Lofexidine can be increased when combined with Belinostat. Lomefloxacin The metabolism of Lomefloxacin can be increased when combined with Belinostat. Lomitapide The serum concentration of Belinostat can be increased when it is combined with Lomitapide. Lomustine The risk or severity of adverse effects can be increased when Lomustine is combined with Belinostat. Lonafarnib The serum concentration of Belinostat can be increased when it is combined with Lonafarnib. Loncastuximab tesirine The serum concentration of Loncastuximab tesirine can be increased when it is combined with Belinostat. Loperamide The serum concentration of Belinostat can be increased when it is combined with Loperamide. Lopinavir The serum concentration of Belinostat can be increased when it is combined with Lopinavir. Lorcaserin The metabolism of Lorcaserin can be increased when combined with Belinostat. Loxapine The serum concentration of Belinostat can be increased when it is combined with Loxapine. Lumacaftor The serum concentration of Belinostat can be decreased when it is combined with Lumacaftor. Lusutrombopag The serum concentration of Lusutrombopag can be increased when it is combined with Belinostat. Magnesium The serum concentration of Magnesium can be decreased when it is combined with Belinostat. Mannitol The serum concentration of Belinostat can be increased when it is combined with Mannitol. Maprotiline The metabolism of Maprotiline can be increased when combined with Belinostat. Maribavir The serum concentration of Belinostat can be increased when it is combined with Maribavir. Measles virus vaccine The therapeutic efficacy of Measles virus vaccine live attenuated can be decreased when used in combination with Belinostat. Mechlorethamine The risk or severity of adverse effects can be increased when Mechlorethamine is combined with Belinostat. Mefenamic acid The metabolism of Mefenamic acid can be increased when combined with Belinostat. Mefloquine The serum concentration of Belinostat can be increased when it is combined with Mefloquine. Melatonin The metabolism of Melatonin can be increased when combined with Belinostat. Meloxicam The risk or severity of methemoglobinemia can be increased when Belinostat is combined with Meloxicam. Melphalan The risk or severity of adverse effects can be increased when Melphalan is combined with Belinostat. Methotrexate The risk or severity of adverse effects can be increased when Methotrexate is combined with Belinostat. Methoxy polyethylene The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Belinostat. Methylene blue The serum concentration of Belinostat can be increased when it is combined with Methylene blue. Methylprednisolone The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Belinostat. Metoclopramide The metabolism of Metoclopramide can be increased when combined with Belinostat. Mexiletine The metabolism of Mexiletine can be increased when combined with Belinostat. Mianserin The metabolism of Mianserin can be increased when combined with Belinostat. Mifepristone The serum concentration of Belinostat can be increased when it is combined with Mifepristone. Mirabegron The serum concentration of Belinostat can be increased when it is combined with Mirabegron. Mirtazapine The metabolism of Mirtazapine can be increased when combined with Belinostat. Mitapivat The metabolism of Belinostat can be increased when combined with Mitapivat. Mitomycin The risk or severity of adverse effects can be increased when Mitomycin is combined with Belinostat. Mitoxantrone The risk or severity of adverse effects can be increased when Mitoxantrone is combined with Belinostat. Moderna COVID The therapeutic efficacy of Moderna COVID-19 Vaccine can be decreased when used in combination with Belinostat. Modified vaccinia ankara The therapeutic efficacy of Modified vaccinia ankara can be decreased when used in combination with Belinostat. Mometasone furoate The risk or severity of adverse effects can be increased when Belinostat is combined with Mometasone furoate. Monomethyl fumarate The risk or severity of adverse effects can be increased when Belinostat is combined with Monomethyl fumarate. Morphine The serum concentration of Belinostat can be increased when it is combined with Morphine. Mosunetuzumab The risk or severity of adverse effects can be increased when Belinostat is combined with Mosunetuzumab. Mumps virus The therapeutic efficacy of Mumps virus strain B level jeryl lynn live antigen can be decreased when used in combination with Belinostat. Muromonab The risk or severity of adverse effects can be increased when Muromonab is combined with Belinostat. Mycophenolate mofetil The risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Belinostat. Mycophenolic acid The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Belinostat. Nabumetone The metabolism of Nabumetone can be increased when combined with Belinostat. Nadroparin The risk or severity of bleeding can be increased when Nadroparin is combined with Belinostat. Naproxen The metabolism of Naproxen can be increased when combined with Belinostat. Natalizumab The risk or severity of adverse effects can be increased when Belinostat is combined with Natalizumab. Nelarabine The risk or severity of adverse effects can be increased when Nelarabine is combined with Belinostat. Nelfinavir The metabolism of Belinostat can be increased when combined with Nelfinavir. Neratinib The serum concentration of Belinostat can be increased when it is combined with Neratinib. Netupitant The serum concentration of Belinostat can be increased when it is combined with Netupitant. Nifedipine The metabolism of Nifedipine can be increased when combined with Belinostat. Nilotinib The metabolism of Belinostat can be decreased when combined with Nilotinib. Nimesulide The risk or severity of bleeding can be increased when Nimesulide is combined with Belinostat. Nintedanib The serum concentration of Nintedanib can be increased when it is combined with Belinostat. Norgestimate The serum concentration of Belinostat can be increased when it is combined with Norgestimate. Nortriptyline The serum concentration of Nortriptyline can be increased when it is combined with Belinostat. Nuvaxovid The therapeutic efficacy of Nuvaxovid can be decreased when used in combination with Belinostat. Obinutuzumab The risk or severity of adverse effects can be increased when Belinostat is combined with Obinutuzumab. Ocrelizumab Ocrelizumab may increase the immunosuppressive activities of Belinostat. Ofatumumab The risk or severity of adverse effects can be increased when Belinostat is combined with Ofatumumab. Olanzapine The metabolism of Olanzapine can be increased when combined with Belinostat. Olaparib The risk or severity of adverse effects can be increased when Belinostat is combined with Olaparib. Omadacycline The serum concentration of Omadacycline can be increased when it is combined with Belinostat. Ombitasvir The metabolism of Belinostat can be decreased when combined with Ombitasvir. Ondansetron The metabolism of Ondansetron can be increased when combined with Belinostat. Osimertinib The serum concentration of Osimertinib can be increased when it is combined with Belinostat. Oxaliplatin The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Belinostat. Oxetacaine The risk or severity of methemoglobinemia can be increased when Belinostat is combined with Oxetacaine. Oxtriphylline The metabolism of Oxtriphylline can be increased when combined with Belinostat. Oxybuprocaine The risk or severity of methemoglobinemia can be increased when Belinostat is combined with Oxybuprocaine. Ozanimod The risk or severity of adverse effects can be increased when Belinostat is combined with Ozanimod. Paclitaxel The risk or severity of adverse effects can be increased when Paclitaxel is combined with Belinostat. Pacritinib The serum concentration of Belinostat can be increased when it is combined with Pacritinib. Palbociclib The risk or severity of adverse effects can be increased when Belinostat is combined with Palbociclib. Palifermin The therapeutic efficacy of Palifermin can be decreased when used in combination with Belinostat. Paliperidone The serum concentration of Belinostat can be increased when it is combined with Paliperidone. Panobinostat The risk or severity of adverse effects can be increased when Belinostat is combined with Panobinostat. Paritaprevir The metabolism of Belinostat can be decreased when combined with Paritaprevir. Parnaparin The risk or severity of bleeding can be increased when Parnaparin is combined with Belinostat. Paroxetine The metabolism of Paroxetine can be increased when combined with Belinostat. Pazopanib The metabolism of Belinostat can be decreased when combined with Pazopanib. Pegaspargase The risk or severity of adverse effects can be increased when Pegaspargase is combined with Belinostat. Pegcetacoplan The risk or severity of adverse effects can be increased when Belinostat is combined with Pegcetacoplan. Peginesatide The risk or severity of Thrombosis can be increased when Peginesatide is combined with Belinostat. Peginterferon alfa-2a The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Belinostat. Peginterferon alfa-2b The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Belinostat. Peginterferon beta-1a The risk or severity of adverse effects can be increased when Belinostat is combined with Peginterferon beta-1a. Pemetrexed The risk or severity of adverse effects can be increased when Pemetrexed is combined with Belinostat. Penciclovir The metabolism of Penciclovir can be increased when combined with Belinostat. Penicillamine The risk or severity of adverse effects can be increased when Penicillamine is combined with Belinostat. Pentosan polysulfate The risk or severity of bleeding can be increased when Pentosan polysulfate is combined with Belinostat. Pentostatin The risk or severity of adverse effects can be increased when Pentostatin is combined with Belinostat. Pentoxifylline The risk or severity of bleeding can be increased when Pentoxifylline is combined with Belinostat. Perampanel The metabolism of Perampanel can be increased when combined with Belinostat. Perphenazine The metabolism of Perphenazine can be increased when combined with Belinostat. Pertussis vaccine The therapeutic efficacy of Pertussis vaccine can be decreased when used in combination with Belinostat. Pexidartinib The metabolism of Belinostat can be decreased when combined with Pexidartinib. Phenindione The risk or severity of bleeding can be increased when Phenindione is combined with Belinostat. Phenobarbital The metabolism of Belinostat can be increased when combined with Phenobarbital. Phenol The risk or severity of methemoglobinemia can be increased when Belinostat is combined with Phenol. Phenprocoumon The risk or severity of bleeding can be increased when Phenprocoumon is combined with Belinostat. Phenylalanine The risk or severity of adverse effects can be increased when Phenylalanine is combined with Belinostat. Phenytoin The metabolism of Belinostat can be increased when combined with Phenytoin. Pibrentasvir The metabolism of Belinostat can be decreased when combined with Pibrentasvir. Pimecrolimus The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Belinostat. Pimozide The metabolism of Pimozide can be increased when combined with Belinostat. Pirfenidone The risk or severity of adverse effects can be increased when Pirfenidone is combined with Belinostat. Pitolisant The serum concentration of Belinostat can be increased when it is combined with Pitolisant. Polythiazide The risk or severity of neutropenia and thrombocytopenia can be increased when Polythiazide is combined with Belinostat. Pomalidomide The risk or severity of adverse effects can be increased when Belinostat is combined with Pomalidomide. Ponatinib The risk or severity of adverse effects can be increased when Belinostat is combined with Ponatinib. Ponesimod The risk or severity of adverse effects can be increased when Belinostat is combined with Ponesimod. Posaconazole The serum concentration of Belinostat can be increased when it is combined with Posaconazole. Pralatrexate The risk or severity of adverse effects can be increased when Belinostat is combined with Pralatrexate. Pralsetinib The serum concentration of Belinostat can be increased when it is combined with Pralsetinib. Pramocaine The risk or severity of methemoglobinemia can be increased when Belinostat is combined with Pramocaine. Prasugrel The risk or severity of bleeding can be increased when Prasugrel is combined with Belinostat. Pravastatin The serum concentration of Belinostat can be increased when it is combined with Pravastatin. Praziquantel The metabolism of Praziquantel can be increased when combined with Belinostat. Prednisolone The risk or severity of adverse effects can be increased when Prednisolone is combined with Belinostat. Prednisolone phosphate The serum concentration of Prednisolone phosphate can be increased when it is combined with Belinostat. Prednisone The risk or severity of adverse effects can be increased when Prednisone is combined with Belinostat. Prilocaine The risk or severity of methemoglobinemia can be increased when Belinostat is combined with Prilocaine. Primaquine The metabolism of Primaquine can be increased when combined with Belinostat. Primidone The metabolism of Belinostat can be increased when combined with Primidone. Probenecid The metabolism of Belinostat can be decreased when combined with Probenecid. Procaine The risk or severity of methemoglobinemia can be increased when Belinostat is combined with Procaine. Procarbazine The risk or severity of adverse effects can be increased when Procarbazine is combined with Belinostat. Promazine The metabolism of Promazine can be increased when combined with Belinostat. Propafenone The serum concentration of Belinostat can be increased when it is combined with Propafenone. Proparacaine The risk or severity of methemoglobinemia can be increased when Belinostat is combined with Proparacaine. Propofol The metabolism of Belinostat can be decreased when combined with Propofol. Propoxycaine The risk or severity of methemoglobinemia can be increased when Belinostat is combined with Propoxycaine. Propranolol The metabolism of Propranolol can be increased when combined with Belinostat. Propylthiouracil The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Belinostat. Protein C The risk or severity of bleeding can be increased when Protein C is combined with Belinostat. Protein S human The risk or severity of bleeding can be increased when Protein S human is combined with Belinostat. Quinidine The serum concentration of Belinostat can be increased when it is combined with Quinidine. Quinine The serum concentration of Belinostat can be increased when it is combined with Quinine. Rabies immune globulin, The therapeutic efficacy of Rabies immune globulin, human can be decreased when used in combination with Belinostat. Rabies virus inactivated The therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Belinostat. Rabies virus inactivated The therapeutic efficacy of Rabies virus inactivated antigen, B can be decreased when used in combination with Belinostat. Raltitrexed The risk or severity of adverse effects can be increased when Raltitrexed is combined with Belinostat. Ramelteon The metabolism of Ramelteon can be increased when combined with Belinostat. Ranitidine The metabolism of Ranitidine can be increased when combined with Belinostat. Ranolazine The serum concentration of Belinostat can be increased when it is combined with Ranolazine. Rasagiline The metabolism of Rasagiline can be increased when combined with Belinostat. Ravulizumab The risk or severity of adverse effects can be increased when Belinostat is combined with Ravulizumab. Regorafenib The metabolism of Belinostat can be decreased when combined with Regorafenib. Relugolix The serum concentration of Relugolix can be increased when it is combined with Belinostat. Reserpine The serum concentration of Belinostat can be increased when it is combined with Reserpine. Reteplase The risk or severity of bleeding can be increased when Reteplase is combined with Belinostat. Revefenacin The serum concentration of Revefenacin can be increased when it is combined with Belinostat. Reviparin The risk or severity of bleeding can be increased when Reviparin is combined with Belinostat. Rifampicin The metabolism of Belinostat can be increased when combined with Rifampicin. Rifamycin The serum concentration of Belinostat can be increased when it is combined with Rifamycin. Rilonacept The risk or severity of adverse effects can be increased when Belinostat is combined with Rilonacept. Riluzole The metabolism of Riluzole can be increased when combined with Belinostat. Rimegepant The serum concentration of Rimegepant can be increased when it is combined with Belinostat. Riociguat The serum concentration of Riociguat can be increased when it is combined with Belinostat. Ripretinib The serum concentration of Belinostat can be increased when it is combined with Ripretinib. Risankizumab The risk or severity of adverse effects can be increased when Belinostat is combined with Risankizumab. Ritonavir The metabolism of Belinostat can be increased when combined with Ritonavir. Rituximab The risk or severity of adverse effects can be increased when Rituximab is combined with Belinostat. Rivaroxaban The serum concentration of Rivaroxaban can be increased when it is combined with Belinostat. Rofecoxib The metabolism of Rofecoxib can be increased when combined with Belinostat. Roflumilast Roflumilast may increase the immunosuppressive activities of Belinostat. Rolapitant The serum concentration of Belinostat can be increased when it is combined with Rolapitant. Romidepsin The serum concentration of Romidepsin can be increased when it is combined with Belinostat. Ropeginterferon alfa-2b The risk or severity of adverse effects can be increased when Belinostat is combined with Ropeginterferon alfa-2b. Ropinirole The metabolism of Ropinirole can be increased when combined with Belinostat. Ropivacaine The risk or severity of methemoglobinemia can be increased when Belinostat is combined with Ropivacaine. Rotavirus vaccine The therapeutic efficacy of Rotavirus vaccine can be decreased when used in combination with Belinostat. Rubella virus vaccine The risk or severity of infection can be increased when Rubella virus vaccine is combined with Belinostat. Rucaparib The metabolism of Rucaparib can be increased when combined with Belinostat. Ruxolitinib The risk or severity of adverse effects can be increased when Belinostat is combined with Ruxolitinib. Sapropterin The serum concentration of Belinostat can be increased when it is combined with Sapropterin. Saquinavir The serum concentration of Belinostat can be increased when it is combined with Saquinavir. Sarecycline The serum concentration of Belinostat can be increased when it is combined with Sarecycline. Sarilumab The risk or severity of adverse effects can be increased when Belinostat is combined with Sarilumab. Satralizumab The risk or severity of adverse effects can be increased when Belinostat is combined with Satralizumab. Secukinumab The risk or severity of adverse effects can be increased when Belinostat is combined with Secukinumab. Selegiline The metabolism of Selegiline can be increased when combined with Belinostat. Selexipag The serum concentration of Selexipag can be increased when it is combined with Belinostat. Selumetinib The serum concentration of Selumetinib can be increased when it is combined with Belinostat. Sildenafil The serum concentration of Belinostat can be increased when it is combined with Sildenafil. Silodosin The serum concentration of Silodosin can be increased when it is combined with Belinostat. Siltuximab The risk or severity of adverse effects can be increased when Belinostat is combined with Siltuximab. Simeprevir The serum concentration of Belinostat can be increased when it is combined with Simeprevir. Simvastatin The serum concentration of Belinostat can be increased when it is combined with Simvastatin. Siponimod The risk or severity of adverse effects can be increased when Belinostat is combined with Siponimod. Sipuleucel-T The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Belinostat. Sirolimus The risk or severity of adverse effects can be increased when Sirolimus is combined with Belinostat. Sitagliptin The serum concentration of Belinostat can be increased when it is combined with Sitagliptin. Smallpox The therapeutic efficacy of Smallpox (Vaccinia) Vaccine, Live can be decreased when used in combination with Belinostat. Sodium aurothiomalate The metabolism of Belinostat can be decreased when combined with Sodium aurothiomalate. Sodium citrate The risk or severity of bleeding can be increased when Sodium citrate is combined with Belinostat. Sofosbuvir The serum concentration of Sofosbuvir can be increased when it is combined with Belinostat. Sorafenib The metabolism of Belinostat can be decreased when combined with Sorafenib. Sotagliflozin The serum concentration of Belinostat can be increased when it is combined with Sotagliflozin. Sotorasib The serum concentration of Belinostat can be increased when it is combined with Sotorasib. Spesolimab The risk or severity of adverse effects can be increased when Belinostat is combined with Spesolimab. Stiripentol The excretion of Belinostat can be decreased when combined with Stiripentol. Streptokinase The risk or severity of bleeding can be increased when Streptokinase is combined with Belinostat. Streptozocin The risk or severity of adverse effects can be increased when Streptozocin is combined with Belinostat. Sulfamethoxazole The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Belinostat. Sulfasalazine The risk or severity of adverse effects can be increased when Sulfasalazine is combined with Belinostat. Sulfinpyrazone The risk or severity of bleeding can be increased when Sulfinpyrazone is combined with Belinostat. Sulodexide The risk or severity of bleeding can be increased when Sulodexide is combined with Belinostat. Sunitinib The risk or severity of adverse effects can be increased when Sunitinib is combined with Belinostat. Suvorexant The serum concentration of Belinostat can be increased when it is combined with Suvorexant. Tacrolimus Tacrolimus may increase the immunosuppressive activities of Belinostat. Talazoparib The serum concentration of Talazoparib can be increased when it is combined with Belinostat. Tamoxifen The metabolism of Tamoxifen can be increased when combined with Belinostat. Tasimelteon The metabolism of Tasimelteon can be increased when combined with Belinostat. Tazemetostat The serum concentration of Tazemetostat can be increased when it is combined with Belinostat. Technetium The serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Belinostat. Tedizolid phosphate The risk or severity of myelosuppression can be increased when Belinostat is combined with Tedizolid phosphate. Tegafur The metabolism of Tegafur can be increased when combined with Belinostat. Tegaserod The serum concentration of Belinostat can be increased when it is combined with Tegaserod. Telaprevir The serum concentration of Belinostat can be increased when it is combined with Telaprevir. Temozolomide The risk or severity of adverse effects can be increased when Temozolomide is combined with Belinostat. Temsirolimus The risk or severity of adverse effects can be increased when Belinostat is combined with Temsirolimus. Tenecteplase The risk or severity of bleeding can be increased when Tenecteplase is combined with Belinostat. Teniposide The risk or severity of adverse effects can be increased when Teniposide is combined with Belinostat. Tenofovir disoproxil The serum concentration of Belinostat can be increased when it is combined with Tenofovir disoproxil. Tepotinib The serum concentration of Belinostat can be increased when it is combined with Tepotinib. Teprotumumab The risk or severity of adverse effects can be increased when Belinostat is combined with Teprotumumab. Terbinafine The metabolism of Terbinafine can be increased when combined with Belinostat. Teriflunomide The risk or severity of adverse effects can be increased when Belinostat is combined with Teriflunomide. Testosterone propionate The metabolism of Belinostat can be increased when combined with Testosterone propionate. Tetracaine The risk or severity of methemoglobinemia can be increased when Belinostat is combined with Tetracaine. Tezacaftor The serum concentration of Tezacaftor can be increased when it is combined with Belinostat. Thalidomide The risk or severity of adverse effects can be increased when Thalidomide is combined with Belinostat. Theophylline The metabolism of Theophylline can be increased when combined with Belinostat. Thiabendazole The metabolism of Thiabendazole can be increased when combined with Belinostat. Thiotepa The risk or severity of adverse effects can be increased when Thiotepa is combined with Belinostat. Thiothixene The metabolism of Thiothixene can be increased when combined with Belinostat. Ticagrelor The serum concentration of Belinostat can be increased when it is combined with Ticagrelor. encephalitis vaccine The therapeutic efficacy of Tick-borne encephalitis vaccine (whole virus, inactivated) can be decreased when used in combination with Belinostat. Ticlopidine The risk or severity of bleeding can be increased when Ticlopidine is combined with Belinostat. Tinzaparin The risk or severity of bleeding can be increased when Tinzaparin is combined with Belinostat. Tioguanine The risk or severity of adverse effects can be increased when Tioguanine is combined with Belinostat. Tipranavir The metabolism of Belinostat can be increased when combined with Tipranavir. Tirofiban The risk or severity of bleeding can be increased when Tirofiban is combined with Belinostat. Tivozanib The serum concentration of Tivozanib can be increased when it is combined with Belinostat. Tixocortol The risk or severity of adverse effects can be increased when Belinostat is combined with Tixocortol. Tizanidine The metabolism of Tizanidine can be increased when combined with Belinostat. Tocainide The metabolism of Tocainide can be increased when combined with Belinostat. Tocilizumab The risk or severity of adverse effects can be increased when Belinostat is combined with Tocilizumab. Tofacitinib Belinostat may increase the immunosuppressive activities of Tofacitinib. Tolvaptan The serum concentration of Tolvaptan can be increased when it is combined with Belinostat. Topotecan The risk or severity of adverse effects can be increased when Topotecan is combined with Belinostat. Toremifene The serum concentration of Belinostat can be increased when it is combined with Toremifene. Tositumomab The risk or severity of adverse effects can be increased when Tositumomab is combined with Belinostat. Trabectedin The risk or severity of adverse effects can be increased when Belinostat is combined with Trabectedin. Trastuzumab Trastuzumab may increase the neutropenic activities of Belinostat. Trastuzumab emtansine The risk or severity of adverse effects can be increased when Belinostat is combined with Trastuzumab emtansine. Tretinoin The risk or severity of adverse effects can be increased when Tretinoin is combined with Belinostat. Triamcinolone The risk or severity of adverse effects can be increased when Triamcinolone is combined with Belinostat. Triamterene The metabolism of Triamterene can be increased when combined with Belinostat. Trichlormethiazide The risk or severity of neutropenia and thrombocytopenia can be increased when Trichlormethiazide is combined with Belinostat. Triclabendazole The metabolism of Triclabendazole can be increased when combined with Belinostat. Trifluoperazine The metabolism of Trifluoperazine can be increased when combined with Belinostat. Trifluridine The risk or severity of adverse effects can be increased when Trifluridine is combined with Belinostat. Triflusal The risk or severity of bleeding can be increased when Triflusal is combined with Belinostat. Trilaciclib The serum concentration of Trilaciclib can be increased when it is combined with Belinostat. Trilostane The risk or severity of adverse effects can be increased when Trilostane is combined with Belinostat. Trimipramine The serum concentration of Trimipramine can be increased when it is combined with Belinostat. Tucatinib Tucatinib may decrease the excretion rate of Belinostat which could result in a higher serum level. Typhoid vaccine The therapeutic efficacy of Typhoid vaccine can be decreased when used in combination with Belinostat. Typhoid Vaccine Live The risk or severity of infection can be increased when Typhoid Vaccine Live is combined with Belinostat. Typhoid Vi polysaccharide The therapeutic efficacy of Typhoid Vi polysaccharide vaccine can be decreased when used in combination with Belinostat. Ubrogepant The serum concentration of Ubrogepant can be increased when it is combined with Belinostat. Umbralisib The serum concentration of Belinostat can be increased when it is combined with Umbralisib. Umeclidinium The serum concentration of Umeclidinium can be increased when it is combined with Belinostat. Upadacitinib The risk or severity of adverse effects can be increased when Belinostat is combined with Upadacitinib. Urokinase The risk or severity of bleeding can be increased when Urokinase is combined with Belinostat. Valproic acid The metabolism of Belinostat can be decreased when combined with Valproic acid. Vandetanib The serum concentration of Belinostat can be increased when it is combined with Vandetanib. Vardenafil The serum concentration of Belinostat can be increased when it is combined with Vardenafil. Varicella zoster vaccine The risk or severity of infection can be increased when Varicella zoster vaccine (live/attenuated) is combined with Belinostat. Varicella zoster vaccine The therapeutic efficacy of Varicella zoster vaccine (recombinant) can be decreased when used in combination with Belinostat. Vedolizumab The risk or severity of adverse effects can be increased when Belinostat is combined with Vedolizumab. Velpatasvir The serum concentration of Belinostat can be increased when it is combined with Velpatasvir. Vemurafenib The serum concentration of Belinostat can be increased when it is combined with Vemurafenib. Venetoclax The serum concentration of Belinostat can be increased when it is combined with Venetoclax. Verapamil The serum concentration of Belinostat can be increased when it is combined with Verapamil. Vibrio cholerae CVD The therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Belinostat. Vilanterol The risk or severity of adverse effects can be increased when Belinostat is combined with Vilanterol. Vinblastine The risk or severity of adverse effects can be increased when Vinblastine is combined with Belinostat. Vincristine The risk or severity of adverse effects can be increased when Vincristine is combined with Belinostat. Vindesine The risk or severity of adverse effects can be increased when Vindesine is combined with Belinostat. Vinflunine The serum concentration of Vinflunine can be increased when it is combined with Belinostat. Vinorelbine The risk or severity of adverse effects can be increased when Vinorelbine is combined with Belinostat. Voclosporin The risk or severity of adverse effects can be increased when Belinostat is combined with Voclosporin. Vorapaxar The serum concentration of Belinostat can be increased when it is combined with Vorapaxar. Vorinostat The risk or severity of gastrointestinal bleeding and thrombocytopenia can be increased when Belinostat is combined with Vorinostat. Voxilaprevir The serum concentration of Belinostat can be increased when it is combined with Voxilaprevir. Warfarin The metabolism of Warfarin can be increased when combined with Belinostat. Pregnancy and Lactation Pregnancy Belinostat can cause fetal harm including teratogenicity and/or embryo-fetal death if administered during pregnancy, based on its mechanism of action. Reproductive animal studies have not been conducted with belinostat and there is no data in pregnant humans; however, it is a genotoxic drug that actively targets dividing cells. Women of childbearing potential should avoid becoming pregnant during treatment with belinostat. Advise pregnant women of the potential hazard to the fetus. Breast-feeding No information is available regarding the presence of belinostat in human milk, the effects on the breastfed child, or the effects on milk production. Due to the potential for serious adverse reactions in the nursing child, breastfeeding is not recommended during therapy or for 2 weeks after the last belinostat dose. How should this medicine be used?

Belinostat comes as a powder to be mixed with liquid to be injected intravenously (into a vein) by a doctor or nurse in a hospital or clinic. It is usually given over a period of 30 minutes once daily on days 1 to 5 of a 21-day cycle. The length of your treatment depends on how well your body responds to the medication and the side effects that you experience. Your doctor may need to adjust your dose or stop…

References

Add references, clinical guidelines, textbooks, journal articles, or trusted medical sources here. You can edit this area from the RX Article Professional Blocks panel.

More from this topic
  1. Vasodilator Drugs

    Vasodilator drugs relax and widen blood vessels, increasing blood flow. A few examples include ACE inhibitors, ARBs, calcium channel blockers, and nitrates.   DefinitionVasodilators are medicines that dilate...

    June 9, 2025 • Drugs (A - Z)
  2. Methamphetamine Hydrochloride – Uses, Dosage, Side Effects, Interaction

    Methamphetamine Hydrochloride is the hydrochloride salt form of methamphetamine, an amphetamine and sympathomimetic amine with CNS stimulating properties. Methamphetamine hydrochloride acts by facilitating the release of catecholamines, particularly noradrenaline and dopamine, from...

    June 5, 2025 • Drugs (A - Z)
  3. Methamphetamine – Uses, Dosage, Side Effects, Interactions

    Methamphetamine is a member of the class of amphetamines in which the amino group of (S)-amphetamine carries a methyl substituent. It has a role as a neurotoxin, a psychotropic drug,...

    June 5, 2025 • Drugs (A - Z)
  4. Vitamin D3 – Uses, Dosage, Side Effects, Interactions

    DefinitionCholecalciferol is a steroid? hormone produced in the skin when exposed to ultraviolet light or obtained from dietary sources. The active form of cholecalciferol, 1,25-dihydroxycholecalciferol (calcitriol) plays an important role...

    March 10, 2025 • Drugs (A - Z)
  5. Imidazole – Uses, Dosage, Side Effects, Interactions

    DefinitionImidazole is an imidazole tautomer which has the migrating hydrogen at position 1. It is a conjugate base of an imidazolium cation. It is a conjugate acid of an imidazolide. It is...

    October 20, 2023 • Drugs (A - Z)
  6. Carbimazole

    Carbimazole is a member of the class of imidazoles that is methimazole in which the nitrogen-bearing hydrogen is converted into its methoxycarbonyl derivative. A prodrug for methimazole, carbimazole is...

    October 20, 2023 • Drugs (A - Z)
  7. Methylthiouracil – Uses, Dosage, Side Effects, Interactions

    DefinitionA thiourea antithyroid agent that inhibits the synthesis of thyroid? hormone. It is used in the treatment of hyperthyroidism?. Methylthiouracil is an organosulfur compound that is used in...

    October 20, 2023 • Drugs (A - Z)
  8. Propylthiouracil – Uses, Dosage, Side Effects, Interactions

    DefinitionPropylthiouracil is a Thyroid? Hormone Synthesis Inhibitor. The mechanism of action of propylthiouracil is as a Thyroid Hormone Synthesis Inhibitor. 6-propyl-2-thiouracil is a pyrimidine-thione consisting of uracil in which the...

    October 20, 2023 • Drugs (A - Z)
  9. Methimazole

    DefinitionMethimazole ( Metirox 5 and 10 mg) is a member of the class of imidazoles that it imidazole-2-thione in which a methyl group replaces the hydrogen that is attached to...

    October 20, 2023 • Drugs (A - Z)
  10. Mirogabalin – Uses, Dosage, Side Effects, Interactions

    DefinitionMirogabalin has been used in trials studying the treatment of Post-herpetic Neuralgia, Pain? Associated With Fibromyalgia, and Diabetic peripheral neuropathic pain. Mirogabalin is a medication designed...

    August 12, 2023 • Drugs (A - Z)